Iovance Biotherapeutics, Inc.

IOVA

As of the close on Sep 25, 2026

Price

$11.00

Market cap

—

The cover-page share count does not match the latest report's share count

P/E (diluted TTM)

—

Per-share earnings are not available for each of the last four quarters

EPS (TTM)

—

Per-share earnings are not available for each of the last four quarters

Dividend yield

—

Dividend records do not yet cover the latest payments

Figures shown here come from public SEC filings. Dates beside each section show the available history.

How Iovance Biotherapeutics, Inc. Makes Money

Follow each dollar of revenue through to what shareholders keep.

From revenue to net income

Pick a year or quarter. Each band's width is its dollar amount.

Source: Iovance Biotherapeutics, Inc. — 10-Q filed Aug 6, 2026

Financial Summary

Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.

Loading financial history…

SEC filings supply these figures; updates after the dates shown are not included. This page includes 18 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 18, 2026.

Ownership

Who holds the shares, as reported in SEC ownership filings.

Purchases & sales (open market or private)

		Security	Code		Price	Filing
2025-06-05	Kirby Daniel Gordon · Chief Commercial Officer	Common Stock	P — Open market or private purchase	+30,000	1.84	SEC filing
2025-05-23	Puri Raj K. · Chief Regulatory Officer	Common Stock	P — Open market or private purchase	+5,600	1.74	SEC filing
2025-05-14	Vogt Frederick G · Interim CEO & General Counsel	Common Stock	P — Open market or private purchase	+25,000	1.69	SEC filing
2024-11-12	Maynard Ryan D · Director	Common Stock	S — Open market or private sale	−50,000	10.06	SEC filing

Showing 4 of 4 rows

Grants, exercises, tax & gifts

		Security	Code		Filing
2026-06-16	Maynard Ryan D · Director	Deferred Restricted Stock Unit	A — Grant, award, or other acquisition	+90,316	SEC filing
2026-06-16	Countouriotis Athena · Director	Deferred Restricted Stock Unit	A — Grant, award, or other acquisition	+90,316	SEC filing
2026-06-16	Dukes Iain D. · Director	Deferred Restricted Stock Unit	A — Grant, award, or other acquisition	+180,632	SEC filing
2026-06-16	WEISER MICHAEL · Director	Deferred Restricted Stock Unit	A — Grant, award, or other acquisition	+90,316	SEC filing
2026-06-16	Puri Raj K. · Chief Regulatory Officer	Restricted Stock Units	A — Grant, award, or other acquisition	+15,000	SEC filing
2026-06-05	BILINSKY IGOR · Chief Operating Officer	Restricted Stock Units	M — Exercise or conversion of derivative security	−7,813	SEC filing
2026-06-05	GRAF FINCKENSTEIN FRIEDRICH · Chief Medical Officer	Common Stock	M — Exercise or conversion of derivative security	+7,813	SEC filing
2026-06-05	Vogt Frederick G · Interim CEO & General Counsel	Restricted Stock Units	M — Exercise or conversion of derivative security	−15,625	SEC filing

Showing 8 of 30 rows

These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.